Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide

British Journal of Cancer

Volumn 73, Issue 11, 1996, Pages 1373-1380

  Asano, T ^a   Zwelling, L A ^a   An, T ^a   McWatters, A ^a   Herzog, C E ^a   Mayes, J ^a   Loughlin, S M ^a   Kleinerman, E S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Drosophila; Etoposide; Human brain tumour; Topoisomerase II; Transfection

Indexed keywords

ANTINEOPLASTIC ALKALOID; DEXAMETHASONE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

ARTICLE; BRAIN TUMOR; CELL GROWTH; COLONY FORMATION; DROSOPHILA; DRUG RESISTANCE; DRUG SENSITIVITY; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE MAMMARY TUMOR ONCOVIRUS; NORTHERN BLOTTING; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0029972110     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.261     Document Type: Article

References (25)

1. BLEYER WA. (1992). Principles of cancer chemotherapy in children. Cancer Bull., 44, 461-469.
2. BUGG BY, DANKS MK, BECK WT AND SUTTLE DP. (1991). Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl Acad. Sci. USA, 88, 7654-7658.
3. CHAMPAIN JA, GOTTESMAN MM AND PASTAN I. (1994). A novel mutant topoisomerase IIα present in VP-16-resistant human melanoma cell lines has a deletion of Alanine 429. Biochemistry, 33, 11327-11332.
4. CHAN VTW, NG S-W, EDER JP JR AND SCHNIPPER LE. (1993). Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem., 268, 2160-2165.
5. EDER JP JR, CHAN VT-W, NIEMIERKO E, TEICHER BA AND SCHNIPPER LE. (1993). Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. J. Biol. Chem., 268, 13844-13849.
6. GEWIRTZ DA. (1991). Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem. Pharmacol., 42, 2253-2258.
7. HERZOG CE, ZWELLING LA, MCWATTERS A AND KLEINERMAN ES. (1995). The expression of topoisomerase II, Bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide. Clin. Cancer Res., 1, 1391-1398.
8. HSIANG Y-H AND LIU LF. (1989). Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J. Biol. Chem., 264, 9713-9715.
9. KAUFMANN SH, MCLAUGHLIN SJ, KASTAN MB, LIU LF, KARP JE AND BURKE PJ. (1991). Topoisomerase II levels during granulocyte maturation in vitro and in vivo. Cancer Res., 51, 3534-3543.
10. KAUFMANN SH, KORP JE, JONER RJ, MILLER CB, SCHNEIDER E, ZWELLING LA, COWAN K, WENDEL K AND BURKE PJ. (1994). Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood, 83, 517-530.
11. KOHN KW, EWIG RAG, ERICKSON LC AND ZWELLING LA. (1981). Measurement of strand breaks and cross-links by alkaline elution. In DNA Repair. A Laboratory Manual of Research Procedures, Frieberg EC and Hanawalt PC (eds), pp.379-401. Marcel Dekker: New York.
12. LEE M-S, WANG JC AND BERAN M. (1992). Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170kDa form of human topoisomerase II. J. Mol. Biol., 223, 837-843.
13. LIU LF. (1989). DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-375.
14. LIU Y-X, HSIUNG Y, JANNATIPOUR M, YEH Y AND NITISS JL. (1994). Yeast topoisomerase II mutants resistant to antitopoisomerases: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res., 54, 2943-2951.
15. MINFORD J, POMMIER Y, FILIPSKI J, KOHN KW, KERRIGAN D, MATTERN M, MICHAELS S, SCHWARTZ R AND ZWELLING LA. (1986). Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry, 25, 9-16.
16. RITKE MK, ROBERTS D, ALLAN WP, RAYMOND J, BERGOLTZ VV AND YALOWICH JC. (1994). Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K 562 cells. Br. J. Cancer, 69, 687-697.
17. ROBINSON MJ AND OSHEROFF N. (1991). Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry, 30, 1807-1813.
18. SCHNEIDER E, HORTON JK, YANG C-H, NAKAGAWA M AND COWAN KH. (1994). Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54, 152-158.
19. SPITZNER JR AND MULLER MT. (1988). A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acid Res., 16, 5533-5556.
20. TAKANO H, KOHNO K, ONO M, UCHIDA Y AND KUWANO M. (1991). Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res., 51, 3951-3957.
21. WANG JC. (1985). DNA topoisomerases. Annu. Rev. Biochem., 54, 665-697.
22. WASSERMAN RA AND WANG J. (1994). Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res., 54, 1795-1800.
23. WEBB CD, LATHAM MD, LOCK RB AND SULLIVAN DM. 1991). Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res., 51, 6543-6549.
24. ZWELLING LA. (1989). Topoisomerase II as a target of antileukemia drugs: a review of controversial areas. Hematol. Pathol., 3, 101-112.
25. ZWELLING LA, HINDS M, CHAN D, MAYES J, SIE KL, PARKER E, SILBERMAN L, RADCLIFFE A, BERAN M AND BLICK M. (1989). Characterization of an amsacrine-resistant line of human leukemia cells: evidence for a drug-resistant form of topoisomerase II. J Biol. Chem., 264, 16411-16420.